AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:08 2024-06-25 am EDT 5-day change 1st Jan Change
12,550 GBX +0.58% Intraday chart for AstraZeneca PLC +1.08% +18.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla... Our Logo
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL CF
AstraZeneca: Tagrisso protocol approved in Japan CF
AstraZeneca: inconclusive trial for Infinzei in NSCL CF
AstraZeneca: conclusive trial in bladder cancer CF
AstraZeneca details mixed findings from cancer drug trials AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan MT
AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial MT
AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial DJ
Mixed bag for Astra drug; Landsec ups Bluewater stake AN
AstraZeneca's Bladder Cancer Combination Treatment Extends Survival in Late-stage Study MT
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer RE
AstraZeneca Provides Update on ADJUVANT BR.31 Phase III Trial of Imfinzi in Non-Small Cell Lung Cancer CI
Astrazeneca Announces Imfinzi Improved EFS and OS in Bladder Cancer CI
BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed into Portfolio CI
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.4 USD
Average target price
174.4 USD
Spread / Average Target
+10.15%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival